Eli Lilly (LLY) Announces Positive Phase 3 Results for Jaypirca Combination in Relapsed CLL/SLL
Corroborated by 2 sources from 2 publishers
globalbusiness5h ago
TL;DR
Reports differ across sources; according to finance.yahoo.com, the safety profile of the regimen was consistent with the known profiles of the individual medicines, with minimal additive toxicity observed when adding pirtobrutinib.